Analysts predict that Albireo Pharma, Inc. (NASDAQ:ALBO) will post $55.00 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Albireo Pharma’s earnings. The company is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Albireo Pharma will report full-year sales of $55.00 million for the current year, with estimates ranging from $5.65 million to $55.00 million. For the next financial year, analysts expect that the firm will post sales of $12.92 million per share. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.23.
Shares of Albireo Pharma stock traded down $1.00 during midday trading on Wednesday, hitting $31.77. The company had a trading volume of 28,079 shares, compared to its average volume of 58,593. The firm has a market capitalization of $389.87, a P/E ratio of -10.09 and a beta of 1.61. Albireo Pharma has a 12-month low of $15.31 and a 12-month high of $39.87.
In other Albireo Pharma news, major shareholder Life Sciences Maste Perceptive purchased 275,000 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were bought at an average price of $33.00 per share, for a total transaction of $9,075,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Phase4 Partners Ltd sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $34.44, for a total transaction of $3,444,000.00. The disclosure for this sale can be found here. 22.30% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. Millennium Management LLC grew its stake in shares of Albireo Pharma by 65.4% during the 4th quarter. Millennium Management LLC now owns 46,594 shares of the biopharmaceutical company’s stock worth $1,193,000 after purchasing an additional 18,425 shares during the period. Ardsley Advisory Partners acquired a new stake in shares of Albireo Pharma during the 4th quarter worth approximately $289,000. Perceptive Advisors LLC grew its stake in shares of Albireo Pharma by 56.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock worth $33,792,000 after purchasing an additional 475,000 shares during the period. Sectoral Asset Management Inc grew its stake in shares of Albireo Pharma by 53.6% during the 4th quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock worth $6,216,000 after purchasing an additional 84,776 shares during the period. Finally, Artal Group S.A. acquired a new stake in shares of Albireo Pharma during the 4th quarter worth approximately $7,680,000. Institutional investors own 29.43% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “$55.00 Million in Sales Expected for Albireo Pharma, Inc. (ALBO) This Quarter” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://weekherald.com/2018/04/22/55-00-million-in-sales-expected-for-albireo-pharma-inc-albo-this-quarter.html.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.